A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Phase ??? Clinical Trial to Evaluate the Efficacy and Safety of LP-003 Injection in Patients With Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Latest Information Update: 08 Feb 2026
At a glance
- Drugs LP 003 Longbio Pharma (Primary)
- Indications Nasal polyps; Rhinosinusitis
- Focus Therapeutic Use
- Sponsors LongBio Pharma
Most Recent Events
- 06 Jan 2026 New trial record